Sorrento

RTK GROUP JOINS THE MASSACHUSETTS BIOTECHNOLOGY COUNCIL

Retrieved on: 
Tuesday, January 31, 2023
Ecosystem, Gout, Sorrento, Patient, Science, Pharmaceutical industry

BOSTON, Jan. 31, 2023 /PRNewswire/ -- RTK Group, LLC, ("RTK Group"), an early-stage advisory and investment fund supporting emerging technologies in the biotech and pharmaceutical sector, today announced it has joined the Massachusetts Biotechnology Council ("MassBio") as a member organization. 

Key Points: 
  • BOSTON, Jan. 31, 2023 /PRNewswire/ -- RTK Group, LLC, ("RTK Group"), an early-stage advisory and investment fund supporting emerging technologies in the biotech and pharmaceutical sector, today announced it has joined the Massachusetts Biotechnology Council ("MassBio") as a member organization.
  • "We are delighted to have RTK Group join MassBio as a member, bringing with them not only years of experience in supporting early-stage startups, but a commitment to improving the lives of patients."
  • RTK Group has been actively advising and providing early-stage financing to startup biopharmaceutical and medical technology companies from early development stages to commercialization.
  • "We look forward to being more actively involved in supporting the life sciences ecosystem through our membership in MassBio," said Neal I. Muni, M.D., MSPH, Managing Director of RTK Group.

Fortress Biotech Appoints David Jin as Chief Financial Officer

Retrieved on: 
Friday, July 22, 2022
IMS Health, Time, Corporation, GLOBE, Corporate development, Degenerative disease, Regulation, SEC, Forward-looking statement, Research, Private equity, Partnership, Fortress Biotech, Securities Act of 1933, Real assets, Private Securities Litigation Reform Act, Securities Exchange Act of 1934, Patent, Management science, Barings LLC, AstraZeneca, City of Hope, COVID-19, Journal, Therapy, NASDAQ, Hospital, Nationwide, FBR, Fred Hutchinson Cancer Research Center, Drug development, Interim, FDA, Company, Social science, Calendar, Patient, Head, City, Mathematical Methods in the Physical Sciences, Drug Quality and Security Act, Growth, Sorrento, Fortification, Renewable energy, Pharmaceutical industry, Fine chemical, Northwestern University, IQVIA

MIAMI, July 22, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress or the Company), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the appointment of David Jin as Chief Financial Officer effective August 16, 2022.

Key Points: 
  • MIAMI, July 22, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (Fortress or the Company), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the appointment of David Jin as Chief Financial Officer effective August 16, 2022.
  • Chairman, President and Chief Executive Officer of Fortress, Lindsay A. Rosenwald, M.D., said, "We are thrilled to expand David's role given the contributions he has made across Fortress and our subsidiaries since joining over two years ago.
  • Mr. Jin has been a core member of the Fortress team since joining in 2020 and also serves as Interim Chief Executive Officer and Chief Financial Officer of Avenue Therapeutics, a Fortress partner company.
  • Fortress Biotech, Inc. (Fortress) is an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates.

CAR T-Cell Therapy Market size worth $ 51408.40 Million, Globally, by 2028 at 63.82% CAGR: Verified Market Research®

Retrieved on: 
Wednesday, June 1, 2022
Aurora, HER1, Sorrento, Research, Juno Therapeutics, ASH, Income, CAR, Acute leukemia, Global, Large intestine, Therapy, Growth, Globe, Geography, Patient, Incidence, Novartis, Industry, Colorectal cancer, Pfizer, Forest Law Enforcement and Governance Program, CAGR, Cancer, USD, Market research, Pharmaceutical industry, Vaccine

JERSEY CITY, N.J., June 1, 2022 /PRNewswire/ --  Verified Market Research recently published a report, "CAR T-Cell Therapy Market" By Targeted Antigen (CD 19, HER1), By Therapeutic Application (Acute Lymphocytic Leukemia, Colorectal Cancer), and By Geography. According to Verified Market Research, CAR T-Cell Therapy Market size was valued at USD 589.99 Million in 2020 and is projected to reach USD 51408.40 Million by 2028, growing at a CAGR of 63.82% from 2021 to 2028.

Key Points: 
  • JERSEY CITY, N.J., June 1, 2022 /PRNewswire/ -- Verified Market Research recently published a report, " CAR T-Cell Therapy Market " By Targeted Antigen (CD 19, HER1), By Therapeutic Application (Acute Lymphocytic Leukemia, Colorectal Cancer), and By Geography.
  • According to Verified Market Research, CAR T-Cell Therapy Market size was valued at USD 589.99 Million in 2020 and is projected to reach USD 51408.40 Million by 2028, growing at a CAGR of 63.82% from 2021 to 2028.
  • The global CAR T-Cell Therapy Market trends and operations are likely to pose major restraints for the market if costs and prices are not reduced, preventing the market from growing as predicted by industry leaders and CAR T-Cell Therapy Market experts during the forecast period.
  • Verified Market Research has segmented the Global CAR T-Cell Therapy Market On the basis of Targeted Antigen, Therapeutic Application, and Geography.

CLOUDCATH EXPANDS EXECUTIVE TEAM WITH KEY NEW HIRE OF CHIEF MEDICAL OFFICER

Retrieved on: 
Wednesday, April 20, 2022
Board, Peritoneal dialysis, International Pediatric Nephrology Association, MD, Board of directors, Entrepreneurship, Machine learning, Patient, ESRD, Dialysis, SAN, Growth, Kidney, Internal medicine, Sorrento, Algorithm, IOT, Multimedia, Acquisition, Quality of life, ARA, Partnership, Partner (business rank), Therapy, PD, Medical device

SAN FRANCISCO, April 20, 2022 /PRNewswire/ -- CloudCath Inc., a private medical device company advancing real-time fluid analytics and remote patient monitoring for peritoneal dialysis (PD), announced today a new addition to their executive leadership team with the hire of Don Williamson, MD as Chief Medical Officer and Executive Vice President of Clinical Services. Dr. Williamson brings 30 years of medical practice and renal industry expertise to the organization to advance the development of the CloudCath solution for remote patient monitoring and managed care of PD patients.

Key Points: 
  • SAN FRANCISCO, April 20, 2022 /PRNewswire/ -- CloudCath Inc., a private medical device company advancing real-time fluid analytics and remote patient monitoring for peritoneal dialysis (PD), announced today a new addition to their executive leadership team with the hire of Don Williamson, MD as Chief Medical Officer and Executive Vice President of Clinical Services.
  • Dr. Williamson brings 30 years of medical practice and renal industry expertise to the organization to advance the development of the CloudCath solution for remote patient monitoring and managed care of PD patients.
  • In addition, Dr. Williamson held multiple executive leadership roles at American Renal Associates (ARA), the fourth largest dialysis provider in the US, including Chief Medical Officer, Executive Vice President, and Chief Operating Officer.
  • CloudCath is a private medical device company advancing real-time fluid analytics and remote patient monitoring of peritoneal dialysis.

Worldwide Intranasal Therapeutics and Drug Delivery Systems Market Distribution to 2035 - Industry Trends and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 15, 2022
Health, Pharmaceutical, Molecule, Therapy, Mortality, Nasal administration, CNS, Partnership, Geography, COVID-19, Sorrento, Brain, BBB, Lists of diseases, USD, Research, Prevalence, Administration, Population, Mucus, Industry, Pharmaceutical industry, Generic drug

The "Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication, Type of Molecule and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Intranasal Therapeutics and Drug Delivery Systems Market Distribution by Target Indication, Type of Molecule and Geography: Industry Trends and Global Forecasts, 2022-2035" report has been added to ResearchAndMarkets.com's offering.
  • This report features an extensive study of the current market landscape and the likely future potential associated with the intranasal therapeutics and drug delivery systems market.
  • Who are the key players engaged in the development of intranasal therapeutics and drug delivery systems?
  • What are the anticipated future trends related to intranasal therapeutics and drug delivery systems?

Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development

Retrieved on: 
Tuesday, March 1, 2022
Pasteur Institute, GLOBE, GMP, University of California, San Diego, Board, Pharmaceutical Development and Technology, University, Therapy, Sorrento, QC, IND, SAS, BAL, Cancer, Patient, Immunotherapy, CEO, Research, CGMP, Pharmaceutical industry

Houston, Texas, USA, March 01, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the needs of cancer patients, today announced the appointment of Jian Cao, Ph.D., as Vice President, Pharmaceutical Development.

Key Points: 
  • Houston, Texas, USA, March 01, 2022 (GLOBE NEWSWIRE) -- Invectys, Inc. of Houston, Texas, a clinical stage immunotherapy company dedicated to the development of a next generation of therapies to meet the needs of cancer patients, today announced the appointment of Jian Cao, Ph.D., as Vice President, Pharmaceutical Development.
  • Dr. Cao brings in extensive experience in biological drug development and GMP manufacturing support of IND through BAL submissions.
  • Before joining Invectys, he was the Acting General Manager for Alvotech & CCHT Biopharmaceuticals Inc., where he led the cGMP manufacturing including process development, manufacturing, QA, QC, regulatory affairs, preclinical and clinical development.
  • Invectys has two wholly owned subsidiaries, Invectys, SAS (Paris) which is focused on scientific research and innovation and Invectys USA, Inc. (Houston) which is directing the clinical development of the Companys lead HLAG product.

Biosimilar Interleukins Global (IL-17, IL-23, IL-1, IL-5, IL-6, Others) Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 21, 2021
Biotechnology, Hospitals, Health, Pharmaceutical, Clinical Trials, Autoimmune disease, IL-5, Growth, Interleukin, Degenerative disease, Cell, British Society for Immunology, Society, Psoriasis, IL-6, Rheumatoid arthritis, Immunology, COVID-19, Asthma, IBD, Inflammatory bowel disease, Incidence, Sorrento, Cancer, Prevalence, Pharmacy, Generic drug, Vaccine

The "Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Biosimilar Interleukins Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Major players in the biosimilar interleukins market are MabPharm, Gedeon Richter, Bio-Thera Solutions, Sorrento Therapeutics/MabTech, and Sunshine Guojian Pharmaceutical.
  • The biosimilar interleukins market consists of sales of interleukin biosimilars generated by the establishments that manufacture interleukin biosimilars that are used to treat various autoimmune diseases.
  • The biosimilar interleukins market covered in this report is segmented by type into IL-17, IL-23, IL-1, IL-5, IL-6, and others.

Kilroy Signs Three New Leases Totaling 330,000 Square Feet of Office-to-Life Science Redevelopments in San Diego

Retrieved on: 
Monday, September 20, 2021
Residential Building & Real Estate, Commercial Building & Real Estate, Construction & Property, REIT, Benchmark, Los Angeles, Securities Act of 1933, Insurance, Policy, Annual report, REIT, Public expenditure, National Association, Trust, Security (finance), Energy Independence and Security Act of 2007, Sorrento, University Town Center, U.S. Securities and Exchange Commission, Pacific Northwest, Securities & Exchange Commission of Pakistan, San Francisco Bay Area, LEED, KRC, Form 10-K, Tenant, National Association of Real Estate Investment Trusts, Acquisition, Legislation, Angelo Gordon, Life, Dow Jones, Tandem Diabetes Care, Risk, KOP, COVID-19, NAREIT, Creativity, Securities Exchange Act of 1934, UTC, Forward-looking statement, Investment, Lists of disasters, NYSE, Industry, Self storage, Property management

Kilroy Realty Corporation (NYSE: KRC, "Kilroy") today announced three new leases totaling 330,000 square feet with publicly traded life science and biotech companies in San Diego.

Key Points: 
  • Kilroy Realty Corporation (NYSE: KRC, "Kilroy") today announced three new leases totaling 330,000 square feet with publicly traded life science and biotech companies in San Diego.
  • Tandem Diabetes Care (~182,000 square feet), DermTech (~96,000 square feet), and Sorrento Therapeutics (~52,000 square feet) lease transactions involve the redevelopment of commercial office space into three state-of-the-art life science/lab facilities and support Kilroy's significant investment in broadening its life science portfolio.
  • Kilroy also plans for a ~600,000 square foot project (Santa Fe Summit) with tech office/life science flexibility on the 56 Corridor to meet the growing demand for space among life science companies in San Diego.
  • In addition, Kilroy had seven in-process development projects with an estimated total investment of $2.9 billion, totaling approximately 3.4 million square feet of office and life science space.

NEXGEL Announces Appointment of Miranda Toledano to Board of Directors

Retrieved on: 
Thursday, September 9, 2021

LANGHORNE, Pa., Sept. 9, 2021 /PRNewswire/ -- NEXGEL, Inc. ("NEXGEL" or the "Company"),a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that the Company has appointed Miranda Toledano to its Board of Directors.

Key Points: 
  • LANGHORNE, Pa., Sept. 9, 2021 /PRNewswire/ -- NEXGEL, Inc. ("NEXGEL" or the "Company"),a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that the Company has appointed Miranda Toledano to its Board of Directors.
  • Ms. Toledano brings over 20 years of biotech, principal investment and capital markets experience to NEXGEL.
  • Since its founding in 2018, Ms. Toledano served as Chief Operating Officer, Chief Financial Officer and Board member at TRIGR Therapeutics, a clinical stage immuno-oncology biotech company, recently acquired by Compass Therapeutics.
  • Toledano is a member of the board of Compass Therapeutics, Entera Bio, Journey Medical and Lipomedix.

Sorrento Mexico and the National Institute of Genomic Medicine (INMEGEN) of Mexico Government Execute Memorandum of Understanding (MOU) for Rapid Clinical Development of COVID-19 Diagnostics, Therapeutics and Multivalent mRNA-Based Vaccines Against SARS-C

Retrieved on: 
Tuesday, August 3, 2021
Life sciences, Biotechnology, Articles, Pharmaceutical industry, Sorrento, Biopharmaceutical

Sorrento Therapeutics Mexico (Sorrento Mexico) and INMEGEN have executed an MOU to further collaborate on clinical development of a broad pipeline of COVID products, including diagnostics, multivalent mRNA-based vaccines and therapeutics.

Key Points: 
  • Sorrento Therapeutics Mexico (Sorrento Mexico) and INMEGEN have executed an MOU to further collaborate on clinical development of a broad pipeline of COVID products, including diagnostics, multivalent mRNA-based vaccines and therapeutics.
  • Sorrento provides its most comprehensive portfolios and a one-stop-shop" of potential solutions for governments interested in a multi-modal detect and treat approach to the COVID-19 pandemic.
  • Sorrento Mexico plans to establish a local research laboratory within INMEGENs facilities to ensure close collaboration between the INMEGEN and Sorrento teams for testing, clinical trials and development of COVID related products.
  • Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19.